Alder BioPharmaceuticals has closed a $38 million Series D financing round. Proceeds of the financing will support clinical development of mAb therapeutic candidates ALD518 and ALD403. The money will also support preclinical studies including a therapeutic targeting PCSK9 for treating dyslipidemia. ALD518, an antibody to the pro-inflammatory cytokine IL-6, is currently being investigated in Phase [...]
↧